Kim Hyeong Seok, Chae Hochang, Lim Soo Yeun, Jeong HyeJeong, Yoon So Jeong, Shin Sang Hyun, Han In Woong, Heo Jin Seok, Kim Hongbeom
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
Int J Surg. 2025 Apr 1;111(4):2962-2972. doi: 10.1097/JS9.0000000000002307.
The incidence of portal vein/superior mesenteric vein (PV/SMV) resection during pancreatoduodenectomy is increasing in clinical practice. This study investigated the clinical significance of preoperative PV/SMV assessment and intraoperative resection and their correlation with pathological results and long-term survival outcomes.
We analyzed 443 patients undergoing pancreatoduodenectomy at a tertiary center from 2012 to 2017 based on PV/SMV resection. Subgroup analyses were performed based on preoperative PV/SMV involvement, resection, and margin status.
Total of 441 patients were analyzed; 175 had PV/SMV involvement on preoperative radiological assessments and 128 underwent PV/SMV resection. True pathological invasion was observed in 78 patients (60.9%), with 34.3% showing no invasion and negative margins. The positive predictive value for preoperative PV/SMV involvement was 61.7%, with a false-negative value of 28.9%. Overall survival of patients who underwent PV/SMV resection was worse than those who did not (2-year survival rate, 38.1% vs 54.9%, P < 0.001). Patients without PV/SMV resection with an rR1/R1 margin showed no decrease in survival compared to those with PV/SMV resection and R0 margins (54.9% vs 40.3%, P = 0.029). Prognostic factors included hypertension, PV/SMV resection, PV/SMV R2 margin, T stage, N stage, cell differentiation, adjuvant treatment, and recurrence.
PV/SMV resection could ensure R0 resection but may lead to unnecessary resection. Careful consideration is essential in determining the need for PV/SMV resection. Poor survival in such patients highlights the need for tailored treatments, including neoadjuvant therapy, for those who are expected to undergo PV/SMV resections.
在临床实践中,胰十二指肠切除术中门静脉/肠系膜上静脉(PV/SMV)切除的发生率正在上升。本研究探讨了术前PV/SMV评估及术中切除的临床意义,以及它们与病理结果和长期生存结局的相关性。
我们基于PV/SMV切除情况分析了2012年至2017年在一家三级中心接受胰十二指肠切除术的443例患者。根据术前PV/SMV受累情况、切除情况及切缘状态进行亚组分析。
共分析了441例患者;175例在术前影像学评估中存在PV/SMV受累,128例接受了PV/SMV切除。78例患者(60.9%)观察到真正的病理侵犯,34.3%未发现侵犯且切缘阴性。术前PV/SMV受累的阳性预测值为61.7%,假阴性值为28.9%。接受PV/SMV切除的患者总生存期比未接受切除的患者差(2年生存率分别为38.1%和54.9%,P<0.001)。未进行PV/SMV切除但切缘为rR1/R1的患者与进行PV/SMV切除且切缘为R0的患者相比,生存率没有降低(54.9%对40.3%,P = 0.029)。预后因素包括高血压、PV/SMV切除、PV/SMV R2切缘、T分期、N分期、细胞分化、辅助治疗和复发。
PV/SMV切除可确保R0切除,但可能导致不必要的切除。在确定是否需要进行PV/SMV切除时,必须仔细考虑。此类患者生存率低凸显了对预期接受PV/SMV切除的患者进行包括新辅助治疗在内的个体化治疗的必要性。